Mesoblast Statistics
Total Valuation
Mesoblast has a market cap or net worth of $1.69 billion. The enterprise value is $1.72 billion.
| Market Cap | 1.69B |
| Enterprise Value | 1.72B |
Important Dates
The last earnings date was Wednesday, August 26, 2026, after market close.
| Earnings Date | Aug 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mesoblast has 1.30 billion shares outstanding. The number of shares has increased by 7.21% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.30B |
| Shares Change (YoY) | +7.21% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 34.17% |
| Owned by Institutions (%) | 25.84% |
| Float | 835.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.09 |
| Forward PS | 8.71 |
| PB Ratio | 2.98 |
| P/TBV Ratio | 832.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.43 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.58 |
Financial Efficiency
Return on equity (ROE) is -9.86% and return on invested capital (ROIC) is -4.51%.
| Return on Equity (ROE) | -9.86% |
| Return on Assets (ROA) | -4.11% |
| Return on Invested Capital (ROIC) | -4.51% |
| Return on Capital Employed (ROCE) | -7.41% |
| Weighted Average Cost of Capital (WACC) | 9.21% |
| Revenue Per Employee | $1.11M |
| Profits Per Employee | -$532,407 |
| Employee Count | 108 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.95 |
Taxes
In the past 12 months, Mesoblast has paid $613,000 in taxes.
| Income Tax | 613,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.59% in the last 52 weeks. The beta is 0.86, so Mesoblast's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -21.59% |
| 50-Day Moving Average | 15.07 |
| 200-Day Moving Average | 15.46 |
| Relative Strength Index (RSI) | 44.61 |
| Average Volume (20 Days) | 282,909 |
Short Selling Information
The latest short interest is 3.30 million, so 3.48% of the outstanding shares have been sold short.
| Short Interest | 3.30M |
| Short Previous Month | 3.31M |
| Short % of Shares Out | 3.48% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 17.02 |
Income Statement
In the last 12 months, Mesoblast had revenue of $120.25 million and -$57.50 million in losses. Loss per share was -$0.45.
| Revenue | 120.25M |
| Gross Profit | 96.22M |
| Operating Income | -51.25M |
| Pretax Income | -56.89M |
| Net Income | -57.50M |
| EBITDA | -44.61M |
| EBIT | -51.25M |
| Loss Per Share | -$0.45 |
Balance Sheet
The company has $102.91 million in cash and $127.33 million in debt, with a net cash position of -$24.42 million or -$0.02 per share.
| Cash & Cash Equivalents | 102.91M |
| Total Debt | 127.33M |
| Net Cash | -24.42M |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | 568.41M |
| Book Value Per Share | 0.44 |
| Working Capital | 116.38M |
Cash Flow
In the last 12 months, operating cash flow was -$43.83 million and capital expenditures -$833,000, giving a free cash flow of -$44.66 million.
| Operating Cash Flow | -43.83M |
| Capital Expenditures | -833,000 |
| Depreciation & Amortization | 6.65M |
| Net Borrowing | -5.94M |
| Free Cash Flow | -44.66M |
| FCF Per Share | -$0.03 |
Margins
Gross margin is 80.02%, with operating and profit margins of -42.62% and -47.82%.
| Gross Margin | 80.02% |
| Operating Margin | -42.62% |
| Pretax Margin | -47.31% |
| Profit Margin | -47.82% |
| EBITDA Margin | -37.09% |
| EBIT Margin | -42.62% |
| FCF Margin | n/a |
Dividends & Yields
Mesoblast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.21% |
| Shareholder Yield | -7.21% |
| Earnings Yield | -3.43% |
| FCF Yield | -2.64% |
Analyst Forecast
The average price target for Mesoblast is $37.00, which is 180.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $37.00 |
| Price Target Difference | 180.73% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 62.83% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 10, 2024. It was a reverse split with a ratio of 1:2.
| Last Split Date | Jan 10, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:2 |
Scores
Mesoblast has an Altman Z-Score of 4.13 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.13 |
| Piotroski F-Score | 4 |